Net sales and earnings declined sharply year-over-year, but equity ratio remains strong. Recent capital raise, scientific recognition, and expanded global presence support ongoing transition from research to clinical applications.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.